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AbstrAct
Objectives Immune recovery following highly active 
antiretroviral therapy (HAART) is commonly assessed by 
the degree of CD4 reconstitution alone. In this study, we 
aimed to assess immune recovery by incorporating both 
CD4 count and CD4:CD8 ratio.
Design Observational cohort study
setting and participants Clinical data from Chinese 
HIV-positive patients attending the largest HIV service in 
Hong Kong and who had been on HAART for ≥4 years were 
accessed.
Main outcome measures Optimal immune outcome was 
defined as a combination of a CD4 count ≥500/μL and a 
CD4:CD8 ratio ≥0.8.
results A total of 718 patients were included for analysis 
(6353 person-years). At the end of year 4, 318 out of 715 
patients achieved CD4 ≥500/μL, of which only 33% (105 
out of 318) concurrently achieved CD4:CD8 ratio ≥0.8. 
Patients with a pre-HAART CD8 ≤800/μL (428 out of 704) 
were more likely to be optimal immune outcome achievers 
with CD4 ≥500/μL and CD4:CD8 ratio ≥0.8, the association 
of which was stronger after adjusting for pre-HAART CD4 
counts. In a multivariable logistic model, optimal immune 
outcome was positively associated with male gender, 
younger pre-HAART age and higher pre-HAART CD4 count, 
longer duration of HAART and pre-HAART CD8 ≤800/μL. 
Treatment regimen and cumulative viral loads played no 
significant role in the pattern of immune recovery.
conclusions A combination of CD4 count and CD4:CD8 
ratio could be a useful approach for the characterisation 
of treatment outcome over time, on top of monitoring CD4 
count alone.
IntrODuctIOn
Highly active antiretroviral therapy (HAART) 
forms the cornerstone of modern-day treat-
ment of HIV infection. In monitoring 
treatment outcome, peripheral blood 
CD4+ lymphocyte (hereafter referred as 
CD4) count measurement is widely used, 
the results of which feature a rapid rise in 
the first 3–6 months followed by a second 
phase of gradual increase, plateauing 4–6 
years afterwards.1 Nadir CD4 counts and 
advanced age are associated with poorer CD4 
recovery, a well-reported phenomenon that 
has been reviewed in the literature.1 2 While 
high and persistently elevated CD8+ lympho-
cytes (hereafter referred as CD8) are 
commonly observed in chronically HIV-in-
fected patients, relatively little attention has 
been paid to its impact on immunological 
recovery.3 A large cohort study suggested that 
markedly elevated CD8 count at HAART initi-
ation was associated with a poor increase in 
CD4 count.4 Host factors aside, virus burden 
exerted by HIV could also impact immuno-
logical recovery. In the absence of timely and 
effective HAART, HIV cumulates over time 
leading to a state of cumulative viraemia, 
a predictor of suboptimal immunological 
outcome in primary HIV infection.5 Separate 
studies have shown that high cumulative viral 
load was a potential marker for progression 
to AIDS in chronic HIV infection.6 Despite 
effective therapy, some 20%–30% of patients 
were unable to achieve optimal immunolog-
ical recovery,1 7 an outcome resulting from 
the interaction of a good range of host and 
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Research
strengths and limitations of this study
 ► The combined use of CD4 and CD4:CD8 ratio as 
an outcome measure offers a new perspective for 
measuring immune recovery following antiretroviral 
therapy.
 ► The combined marker could avoid overestimation of 
treatment performance in patients with CD4 count 
but low CD4:CD8 ratio.
 ► The study was limited by not having included clinical 
events in the analysis, a gap which should be filled 
in larger scale cohort studies.
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viral factors, as well as coinfection with other pathogens, 
notably hepatitis C virus (HCV).3
Over the last decade, a CD4-guided approach to 
treatment initiation has gradually been replaced by 
early initiation of HAART irrespective of baseline CD4 
level.8 Achievement of a high CD4 count of, say, over 
500/μL remains a commonly used marker of immune 
restoration. Knowingly, prompt treatment and full viral 
suppression do not imply freedom from comorbidities, 
as HIV disease is also characterised by a state of immune 
activation, with the emergence of non-AIDS morbidity 
and mortality.9 This morbid state of immune activation 
cannot be inferred from the pattern of CD4 recovery 
alone. Failure of CD4/CD8 normalisation following 
HAART has however been linked to this scenario of 
immune activation.10 11 Low CD4:CD8 ratio was observed 
in patients despite high CD4 level (>500/μL).12 A high 
CD8 count following HAART was shown to be associated 
with inflammatory non-AIDS-related clinical events, and 
in fact a higher risk of myocardial infarction has been 
reported.4 13 Apparently, a target CD4 count is inadequate 
for reflecting effective immune recovery. Concurrent rise 
of the CD4:CD8 ratio is increasingly recognised as an 
important marker of immune reconstitution.10 14
To better monitor immunological recovery following 
HAART, new biomarkers are needed, which should pref-
erably be derived from routinely collected laboratory 
data. Optimal outcome could be founded on CD4/CD8 
normalisation on top of the regularly monitored CD4 
count. In this study, we define HAART-associated immune 
recovery by a combination of CD4 outcome and CD4/
CD8 restoration. We set out to examine its predictors by 
analysing regularly collected viral load and immunolog-
ical data, the latter including CD8 count, in a cohort of 
patients with HIV following HAART.
MethODs
Anonymous clinical data from Integrated Treatment 
Centre, the largest HIV clinical service in Hong Kong, were 
accessed for this observational study. Data access approval 
was granted by the Department of Health, Hong Kong 
Special Administrative Region Government in compliance 
with the Personal Data (Privacy) Ordinance. Individual 
consent for the study was waived following approval of the 
Joint Chinese University of Hong Kong–New Territories 
East Cluster Clinical Research Ethics Committee. Patients 
with HIV aged ≥18 diagnosed in 1985–2012, on HAART 
continuously for ≥4 years without treatment interruption, 
with at least one CD4 measurement during treatment and 
with viral load fully suppressed (without consecutive viral 
load >500 copies/mL in the first 4 years on treatment) 
were selected. We included patients who were treatment 
naïve or have been on non-standard treatment for <1 year 
before HAART initiation. Data retrieved were: (A) CD4 
and CD8 counts at diagnosis, before HAART initiation 
and 3–4 months subsequently, (B) viral load levels at 
the respective time points, (C) AIDS diagnosis and the 
timing, as appropriate, (D) antiretroviral treatment date 
and regimens, differentiated as protease inhibitor (PI) or 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 
based as other regimens were rarely used for treat-
ment-naïve patients.
Estimated cumulative viral load was expressed as 
years×log10 copies/mL, in accordance with the method 
reported by Zoufaly et al15 with modifications. Patients 
with available negative HIV testing result within 3 years 
before HIV diagnosis were included, so that one’s sero-
conversion date could be estimated with confidence.16 In 
brief, the products of the log10 viral load were summed 
from estimated seroconversion to subsequent specified 
time point(s), with the computation of the highest viral 
load for the undiagnosed interval and an upward adjust-
ment by 1 log10 for the presumed primary infection 
period. The time of seroconversion was determined as the 
midpoint between last negative and first positive HIV anti-
body testing dates. On the other hand, optimal immune 
outcome was defined as the achievement of a CD4 count 
of ≥500/μL and a CD4:CD8 ratio ≥0.817 while conven-
tional outcome was defined as achieving CD4 count 
of ≥500/μL but not CD4:CD8 ratio ≥0.8 within specific 
time. Late HIV diagnosis was defined as the diagnosis of 
AIDS within 3 months of HIV diagnosis. The latest CD4 
and CD8 measurements ≤30 days before HAART initia-
tion were used as the baseline.
Comparisons between pre-HAART CD8 >800/μL 
vs ≤800/μL were made by OR and multivariable logistic 
regression with pre-HAART CD4 as confounder, while 
correlation coefficients were calculated to test the asso-
ciations between CD4 and CD8 before and 4 years after 
HAART. The CD8 threshold was adopted by taking refer-
ence from the criteria of high CD8 count (ie, over 800/
μL) during primary infection reported in another study.18 
CD4 (maximum value), CD8 (minimum value) and 
CD4:CD8 ratio (maximum value) of patients achieving 
optimal immune outcome and conventional outcome 
by year 4 on HAART over time (≤12 months, 12.1–24 
months, …, >96 months) were compared in gener-
alised estimating equations (GEE). Multivariable logistic 
regression model (stepwise) was applied to examine the 
predictors of optimal immune outcome and conventional 
outcome. Complete case analysis was performed. Loss to 
follow-up and death were data end points. Statistical tests 
were performed in SPSS 21.
results
As of the end of 2012, data of 2974 diagnosed adults 
were accessed. Of these, 718 eligible treatment-naïve 
diagnosed cases who had been on HAART continuously 
for ≥4 years were included in the study. Their case records 
contained 18 857 clinical measurements (18 693 CD4, 
18 521 CD8 and/or 17 776 viral load measurements) at 
multiple time points spanning over 6353 person-years’ 
follow-up. General characteristics of the study population 
are displayed in table 1. Overall, a majority (84%) were 
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Table 1 General characteristics of study population 
(n=718)
Frequency %
Median (IQR)
(a) Demographics
Male gender 605 84%
Ethnicity
  Chinese 581 81%
  Asian (Asian other than 
Chinese)
87 12%
  White 47 7%
  African 3 0.4%
  Age (years, at HIV diagnosis) 37 (31–45)
(b) HIV infection and diagnosis
Mode of transmission
  Heterosexual 394 55%
  Man-to-man sex 280 39%
  Injection drug use 34 5%
  Contaminated blood 
transfusion
6 1%
  Undetermined 4 1%
HIV-1 subtype
  CRF01_AE 270 38%
  B 224 31%
  C 8 1%
  Others 31 4%
  Unavailable 185 26%
AIDS diagnosis before treatment 239 33%
Late HIV diagnosis* 192 27%
Estimated cumulative viral 
load† from seroconversion to 
diagnosis (n=199)
8 (3–18)
(c) Pre-HAART status
Age (years) 39 (33–46)
Months from diagnosis to 
treatment initiation
8.67 (2.75–33.13)
CD4 count (cells/µL) 109 (29–190)
CD4:CD8 ratio‡ 0.14 (0.06–0.23)
CD8 count (cells/µL)‡ 673 (441–966)
Viral load (log10 copies/mL)§  5.15 (4.62–5.58)
Estimated cumulative viral 
load† from seroconversion to 
treatment initiation (n=199)
18 (11–29)
(d) Antiretroviral treatment and 
clinical outcomes
First HAART regimen
  NNRTI based 182 25%
  PI based 131 18%
  PI based with booster 397 55%
  Non-standard 8 1%
Total treatment duration (months) 85.38 (63.39–117.32)
Continued
Frequency %
Median (IQR)
AIDS free during treatment 
(n=479)
456 95%
Highest CD4 count within 
4 years¶
476 (354–630)
Highest CD4:CD8 ratio within 
4 years**
0.55 (0.39–0.76)
CD4 count ≥500/μL within 
4 years¶
318 44%
CD4:CD8 ratio ≥0.8 within 
4 years††
145 20%
  Deceased 39 5%
*Late HIV diagnosis refers to the diagnosis of AIDS within 3 months 
of HIV diagnosis.
†Estimated cumulative viral load expressed as years×log10 viral 
load copies/mL.
‡14 missing values.
§18 missing values.
¶2 missing values.
**8 missing values.
††3 missing values.
HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; PI, protease inhibitor.
Table 1 Continued 
male with a median age at diagnosis of 37 years (IQR: 
31–45 years). The median interval from diagnosis to the 
latest assessment was 100 months (IQR=74–141 months). 
Most were infected by either HIV-1 subtype B (31%) 
or CRF01_AE (38%), with men who have sex with men 
(MSM) accounting for 39% of the study population. The 
pre-HAART median CD4 and CD8 counts were 109/μL 
and 673/μL, respectively, which were positively correlated 
(Pearson correlation coefficient r=0.50, p<0.001) (see 
online supplementary figure 1d). The distribution of 
CD4 and CD4:CD8 ratio at baseline before initiation of 
HAART is shown in online supplementary table 1a. The 
lifetime estimated cumulative viral load at the last assess-
ment increased with the interval between seroconversion 
and HAART initiation (r=0.94, p<0.001).
During the study period, a CD4-guided approach was in 
place, implying that HAART was recommended when one’s 
CD4 count fell below 350/μL. A majority of the patients 
(74%) had been started on a PI-based regimen with 25% 
on NNRTI-based regimen, and 1% had been started on 
non-standard regimen subsequently changed to HAART 
within 1 year. Integrase inhibitors (INSTI) had not been 
used as a component of one’s first regimen, but three 
patients had changed to raltegravir-based regimen after-
wards (table 1). The median treatment duration was 85.38 
months (IQR: 63.39–117.32). As of the end of a 4-year 
observation period, the CD4 count of 318 patients (44%) 
had reached 500/μL or above, of which 105 (33%) gave 
a CD4:CD8 ratio of ≥0.8 concurrently, while 205 (64%) 
patients reached the CD4 target but not the ratio. On the 
other hand, 145 patients reached the optimal ratio, of 
which 32 (22%) patients could not reach the CD4 target 
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Table 2 The profiles of immunological outcomes of patients by achievement of none, one or both of the two target 
immunological markers (CD4 ≥500, CD4:CD8 ratio ≥0.8) before the end of a 4-year observation period*
Number
Median peak or 
highest CD4 count 
(/μL) (IQR)
Median months  
to CD4 target (IQR)
Median peak or highest 
CD4:CD8 ratio (IQR)
Median months to target 
CD4:CD8 ratio (IQR)
CD4 ≥500/μL and 
CD4:CD8 ratio ≥0.8 105 741 (618–876) 20.63 (12.6–30.53) 0.98 (0.86–1.2) 28.90 (14.43–42.95)
Concurrent 
achievement of both 
targets 15 694 (569–1182) 20.27 (13.07–28.17) 1.05 (0.9–1.49) 20.27 (13.07–28.17)
CD4 target before 
ratio target 57 788 (660–921) 15.13 (8.7–22.88) 0.89 (0.83–0.99) 39.23 (30.78–45.98)
Ratio target before 
CD4 target 33 650 (547–764) 31.13 (22.3–39.4) 1.17 (1.02–1.56) 14.40 (8.68–24.08)
CD4 ≥500/μL only 205 622 (552–723) 29.10 (17.43–38.37) 0.59 (0.49–0.69) –
Ratio ≥0.8 only 32 431 (369–475) – 1.05 (0.89–1.17) 29.32 (18.48–40.33)
CD4 target then 
changed to ratio 
target 4 588 (519–660) 20.02 (12.23–35.36) 0.86 (0.81–0.95) 36.83 (20.68–49.72)
Ratio target then 
changed to CD4 
target 4 583 (521–636) 29.68 (20.52–40.38) 0.87 (0.86–1.01) 13.87 (5.48–25.45)
Failure to achieve 
both targets 365 362 (253–432) – 0.43 (0.31–0.55) –
*Equivalent to a maximum of <52 months with the inclusion of a 3-month buffer period.
(table 2). The temporal changes of CD4 count, CD8 
count and CD4:CD8 ratio over time are shown in figure 1, 
while distribution of CD4 and CD4:CD8 ratio at the end 
of year 4 is shown in online  supplementary table 1b. 
Whereas both CD4 count (figure 1A) and CD4:CD8 ratio 
(figure 1C) showed a steady rise from the first time point 
following HAART, the temporal pattern of CD8 counts 
was inconspicuous (figure 1B). Patients with optimal 
immune outcome had significantly higher median CD4 
and CD4:CD8 ratio but lower CD8 count than those only 
with satisfactory CD4 recovery (conventional outcome) in 
all time points (GEE model results in online supplemen-
tary table 2 supplementary table 1). The CD4 count at year 
4 was positively correlated with pre-HAART CD4 (r=0.38, 
p<0.001) (see online supplementary figure 1a). Catego-
rised by one’s pre-HAART CD8 count, about half (n=428, 
61%) had a lower count of ≤800/μL. The two groups 
had similar demographic, cumulative viral load levels 
and had received similar treatment regimens. The CD4 
count at year 4 was positively correlated with pre-HAART 
CD8 count (r=0.18, p<0.001) (see online supplementary 
figure 1b) whereas the latter was also positively correlated 
with CD8 at year 4 (r=0.35, p<0.001) (see online supple-
mentary figure 1c). After adjusting for pre-HAART CD4, 
patients with lower pre-HAART CD8 had a higher chance 
of achieving a higher CD4:CD8 ratio at year 4 (adjusted 
OR (aOR)=64.63, 95% CI 23.47 to 177.98) (table 3). Like-
wise, a low pre-HAART CD8 count of ≤800/μL was asso-
ciated with the optimal immune outcome at year 4, with 
an increased odds (aOR=5.07, 95% CI 2.74 to 9.41) after 
adjusting for pre-HAART CD4. There was no significant 
correlation between year 4 CD8 and pre-HAART CD4 
(see online supplementary figure 1e), but positive associ-
ation between CD4 and CD8 at year 4 (r=0.33, p<0.001) 
could be demonstrated (see online supplementary figure 
1f).
The following independent variables were then tested 
for their prediction of optimal immune outcome and 
conventional outcome achieved since treatment initi-
ation throughout the observation period: pre-HAART 
CD4, pre-HAART CD8, pre-HAART age, treatment dura-
tion and male gender. In the final model, both high 
pre-HAART CD4 and low pre-HAART CD8 were signifi-
cant predictors of optimal immune outcome, while only 
the former was a significant predictor of conventional 
outcome (table 4). Patients who were male and started 
HAART at younger age were more likely to achieve both 
outcomes. Patients on treatment for longer time (≥97 
months) had higher odds to achieve optimal immune 
outcome (aOR=3.34, 95% CI 2.17 to 5.15, 49–72 months 
as reference) than conventional outcome (aOR=2.78, 
95% CI 1.89 to 4.09, 49–72 months as reference). As a 
substudy (results not shown), we have performed another 
set of GEE models with cumulative viral load as an inde-
pendent variable (results not shown). The results did not 
support it as a significant predictor of an optimal immune 
outcome both in CD4 count and CD4:CD8 ratio, though 
the number of patients eligible for the analyses was only 
187.
DIscussIOn
Pre-HAART CD4 count has long been shown to be a 
predictor of immunological outcome 3–5 years following 
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Figure 1 Yearly changes of (A) CD4 count, (B) CD8 count and (C) CD4:CD8 ratio from HAART initiation to 6 years afterwards.  
HAART, highly active antiretroviral therapy.
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antiretroviral therapy.1 Our previous longitudinal studies 
in a cohort of Chinese patients with HIV have demon-
strated positive associations between nidus and maximum 
CD4 count over 5 years irrespective of the causative virus 
subtype or the regimens prescribed.19 20 In assessing 
antiretroviral treatment response, however, CD4 count 
alone appeared to add little to viral load monitoring.21 To 
account for the potential risk of non-AIDS-related comor-
bidities including metabolic complications,9 parallel 
CD4:CD8 ratio testing is gaining popularity as it reflects 
also the intensity of chronic inflammation implicated.9 10 
In this study, a CD4 count ≥500/μL in conjunction with a 
ratio of ≥0.8 was examined as a target outcome indicator 
for chronically infected patients on continued antiretro-
viral therapy. This target was achieved in 15% (105 out 
of 715) of our patients at the end of a 4-year treatment 
period. The association of pre-HAART CD8 with optimal 
immune outcome was stronger with a cut-off ratio 
of ≥1 but the proportion of patients achieving the target 
outcome would be very low at 6% (46 out of 718). Both 
pre-HAART CD4 and CD8 counts, as well as the treat-
ment interval, were independent predictors of this new 
outcome target. While CD4 remained a useful prognostic 
marker, using it as the sole marker might overestimate 
treatment performance by including patients with high 
CD4 count but high CD8 count and low CD4:CD8 ratio as 
achiever (205 out of 715 achieved CD4 target only).
In this study, we have shown that 44% of patients on 
HAART achieved a CD4 count ≥500/μL at the end of 4 
years, an outcome slightly poorer than that of 59% reported 
by the Swiss HIV Cohort Study, a discrepancy which could 
be attributed to our shorter observation period (4 instead 
of 5 years) and the lower median pre-HAART CD4 count 
(158/μL compared with 180/μL).22 As concluded in the 
recently published ‘START’ study examining the bene-
fits of the initiation of antiretroviral therapy in HIV-pos-
itive adults with a CD4 count >500/μL, CD4 count per 
se could not capture all outcome effects arising from 
immediate HAART in chronic HIV infection.23 Our study 
confirmed that CD4:CD8 ratio could be a readily avail-
able supplementary marker to monitor immune recovery. 
Evidently, the ratio may vary with lengths of observations, 
demographics and/or even HAART regimens.17 24 25 
As the CD4:CD8 ratio tended to rise more slowly than 
CD4 recovery, we have chosen an interim ratio of 0.817 
to assess the state of immune recovery at 4 years after 
HAART initiation. Normalisation to a ratio of 1 could in 
fact be demonstrated in 13% of patients within 7 years, 
the median observation interval of our cohort.
Pre-HAART CD8 count and its normalisation following 
antiretroviral treatment are relatively underinvesti-
gated.26 27 In our study, pre-HAART CD4 and pre-HAART 
CD8 counts were positively correlated. It was noted that 
heterosexuals gave a lower pre-HAART CD8 (table 3) 
compared with MSM but the difference became insig-
nificant after the adjustment of pre-HAART CD4. 
Over time, CD4 rise went in parallel with slowly falling 
CD8 until reaching an optimal CD4 level of ≥500/μL 
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Table 4 Multivariable logistic regression for evaluating variables associated with an optimal immunological outcome and 
conventional outcome
Optimal immune outcome Conventional outcome
aOR 95% CI aOR 95% CI
Male gender 2.23 1.4 to 3.53* 1.81 1.11 to 2.96*
Age at HAART initiation 0.98 0.97 to 0.9996* 0.96 0.94 to 0.97*
Pre-HAART CD4 (/μL)
  ≤100 Ref Ref
  101–200 2.91 1.83 to 4.62* 2.30 1.57 to 3.37*
  201–300 4.61 2.53 to 8.39* 3.52 2.1 to 5.9*
  >300 20.36 7.51 to 55.17* 12.84 3.6 to 45.75*
Months on treatment
  49–72 Ref Ref
  73–96 1.58 0.93 to 2.67 1.67 1.08 to 2.57*
  ≥97 3.34 2.17 to 5.15* 2.78 1.89 to 4.09*
Pre-HAART CD8 ≤800/μL 0.998 0.998 to 0.999*
Constant 0.48 3.30
An optimal immunological outcome was defined as achieved CD4 count ≥500/μL and a CD4:CD8 ratio ≥0.8, and conventional outcome was 
defined as only achieved CD4 count ≥500/μL by study end point.
*p<0.05.
aOR, adjusted OR; HAART, highly active antiretroviral therapy.
with a near-normalised CD4:CD8 ratio ≥0.8 at year 4. 
Pre-HAART CD8 was a significant predictor of optimal 
immune outcome but not conventional outcome. The 
median CD8 count of former group was lower than 
latter group of patients in all time points since HAART 
initiation. Significant expansion of CD8 is known to 
occur soon after infection and the phenomenon might 
persist throughout the course of HIV infection. Recent 
studies suggested that CD8 normalisation was associated 
with early initiation of HAART during acute infection.18 
HIV-specific CD8 has been proposed to play an important 
role in effecting functional cure of HIV infection.28 Its 
relationship with the absolute count of CD8 before and 
after HAART has not been established. With the growing 
evidence of the role of CD4:CD8 ratio as a new biomarker 
for non-AIDS morbidity and chronic inflammation,9 10 29 30 
it is possible that HIV-positive patients’ clinical outcome 
could be better explained from both the ratio and CD4 
count rather than from the latter alone. From a virolog-
ical perspective, the estimated cumulative viral load can 
be viewed as a surrogate of prolonged non-suppression 
of virus load. It does not however independently predict 
CD4 or CD4:CD8 ratio outcomes. Apparently, its immu-
nological impacts could be overtaken by a long interval 
of HAART, if the pre-HAART CD4 and CD8 status 
were optimal. Overall, our results lent support to early 
initiation of HAART in chronic HIV infection to avoid 
temporal accumulation of virus, a conclusion similar to 
that for primary HIV infection.5
We acknowledge that our study carries a number of 
limitations. Foremost, all patients had been on HAART 
during the time when a CD4-guided approach to treatment 
initiation was enforced. As the patients had been started 
on either a PI-based or NNRTI-based regimen, the 
possible impacts of newer generations of antiretroviral 
like INSTI could not be ascertained. The results should 
therefore be interpreted with caution, especially that 
strong association between INSTI-based regimen and 
CD4/CD8 normalisation has recently been reported.31 
These was selection bias which might have limited the 
extrapolation of results to the entire HIV population. In 
addition, our dataset did not include other inflammatory 
or infectious outcomes (eg, HCV and/or cytomegalovirus 
coinfections32–35) and therefore these could not be anal-
ysed in perspective. As the main comparative period was 
4 years, the minimum treatment duration of study popu-
lation, the immunological recovery achieved by patients 
in this study may not necessarily be reflecting the ultimate 
response to HAART. We have nevertheless evaluated the 
outcome (comprising both CD4 count and CD4:CD8 
ratio) of all enrolled patients with a median duration of 
treatment of over 6 years in the final analysis. Theoret-
ically, cohorts with patients observed throughout their 
lifetime would be invaluable to determine the health 
benefits of HAART. Analyses from such lifelong cohorts 
should become a reality in the coming years or decades.
cOnclusIOns
Conventionally, CD4 count has been commonly used as 
the main outcome marker following HAART. In light 
of the increasing incidence of comorbidities associated 
with HIV-related chronic inflammations, CD4 count per 
se appears to carry little prognostic value in predicting 
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HAART-associated immune recovery. Our results suggested 
that a combination of CD4 count and CD4:CD8 ratio offers 
another potentially useful approach to assessing immune 
outcome, compared with the use of CD4 alone. In eval-
uating immune recovery following long-term HIV viral 
suppression, pre-HAART CD8 count could be as important 
as nidus CD4 count as the independent predictors of the 
ultimate immune outcome. As both CD4 and CD8 are often 
routinely collected in the course of HIV management, 
an assessment of the temporal trends of CD4, CD8 and 
CD4:CD8 ratio could conveniently predict the immunolog-
ical outcome without the need for sophisticated immune 
markers. Virological impact, as inferred from the estimated 
cumulative viral load after infection, does not however add 
to the outcome reflected from viral load suppression. The 
monitoring of the host immunological responses remains 
the most important approach in assessing treatment 
outcome following HAART.
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